Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
NPR · LC · trust 72/100
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Read the original at NPR →
Open in TruthVane →